Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-366-296"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-366-296"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-366-3122
lpv:speaker	lp:Zigmantas Balčytis2
lpv:spokenAs	member; ITRE (2012-01-19--2014-06-30)3 member; S&D (2009-07-14--2014-06-30)3 unknown; Lietuvos socialdemokratų partija (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the United States (2009-09-16--2014-06-30)3 substitute; TRAN (2012-01-19--2014-06-30)3 member; Delegation for relations with the People's Republic of China (2009-09-16--2014-06-30)3 member; CONT (2012-01-19--2014-06-30)3
lpv:translated text	"I voted in favour of this report, which is aimed at adopting new measures to help strengthen pharmacovigilance throughout the EU and ensure greater safety of medicines across the EU. Monitoring the safety of medicines is aimed at determining and evaluating the side effects of medicines, thus stopping unsuitable medicines from entering the market. The need to ensure the safety of medicines arose following the 2011 inquiry in France into the drug Mediator produced there, the effects of which are thought to have led to the death of between 500 and 2 000 people across the EU. I therefore welcome the strengthening of medicine safety, particularly the obligation to make public a list of the medicinal products for which marketing authorisations have been refused, revoked or suspended, the supply of which has been prohibited or which have been withdrawn from the market, as well as other measures to protect patients provided for in the directive."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph